Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
MWN-AI** Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is set to present new long-term efficacy and safety data regarding its gene therapy and exon-skipping programs for Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association (MDA) Clinical & Scientific Congress from March 8 to 11, 2026, in Orlando, Florida. As a leader in precision genetic medicine targeting rare diseases, Sarepta's presentation will feature a late-breaking oral session focused on the delandistrogene moxeparvovec gene therapy from the Phase 3 EMBARK study, revealing results up to three years post-infusion compared to matched external controls.
In addition, the company will highlight caregiver-reported perspectives on treatment impact from the EMBARK study, complementing clinician-reported outcomes. A pivotal safety analysis encompassing up to 7.5 years of follow-up will feature treatment-related adverse events primarily occurring within the first 60 days post-infusion.
Sarepta’s presentations will also cover data from its exon-skipping franchise, including Phase 3 results from the ESSENCE study for golodirsen and casimersen. Real-world data will be shared as well, analyzing long-term safety and loss of ambulation from the ongoing Phase 4 EVOLVE study.
Dr. Louise Rodino-Klapac, Sarepta's president of research & development, emphasized the significance of understanding dystrophin restoration as a foundational therapy for DMD. The goal is to empower clinicians and families with comprehensive data to make informed treatment choices.
The MDA congress will provide the platform for Sarepta to disseminate important findings, enhancing details on the efficacy, safety, and real-world implications of its therapeutic approaches. For additional information, updates will be available on Sarepta's website post-conference.
MWN-AI** Analysis
As Sarepta Therapeutics (NASDAQ: SRPT) prepares to unveil pivotal findings at the 2026 Muscular Dystrophy Association Clinical & Scientific Congress, investors should consider the implications of data presented from its gene therapy and exon-skipping programs for Duchenne muscular dystrophy (DMD). The company's late-breaking presentation on delandistrogene moxeparvovec’s efficacy and safety, alongside long-term data from the Phase 3 EMBARK study, has the potential to significantly impact investor sentiment and stock performance.
The results of the EMBARK study, particularly with a follow-up of three years post-infusion, may reinforce the treatment's viability in clinical practice. Presenting caregiver-reported data emphasizes the real-world impact of their therapies, which can drive a deeper understanding of treatment outcomes beyond clinical efficacy alone. Investors should be cautious yet optimistic; successful results could stimulate higher market confidence, while any adverse findings could lead to volatility.
Sarepta's commitment to transparency with pooled safety data—covering up to 7.5 years of follow-up—demonstrates a responsible approach to risk disclosure, potentially mitigating investor apprehension about long-term safety. The diverse array of findings across its exon-skipping portfolio adds another layer of robustness, illustrating Sarepta's leadership in genetic medicine.
As the biotech landscape continues to prioritize innovative treatments, particularly for rare diseases, Sarepta's findings could catalyze broader acceptance and regulatory support for gene therapies. Given the momentum around its clinical presentations, investors might view any price dips as buying opportunities, aligning with long-term perspectives on genetic treatments' market potential. However, prudent consideration of inherent risks highlighted in Sarepta's forward-looking statements remains essential for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Several abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrophin restoration and its impact in Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8 - 11, 2026, in Orlando, Florida.
At MDA 2026, Sarepta will present new and ongoing evidence across its rare neuromuscular portfolio, including commercially available gene therapy and exon-skipping treatments in Duchenne muscular dystrophy. Presentations include a late-breaking oral presentation on delandistrogene moxeparvovec gene therapy from the Phase 3 EMBARK study (Part 1) up to three years post-infusion compared with a matched external control. Another abstract will feature caregiver-reported impressions from the Phase 3 EMBARK study through two years of follow-up, offering complementary perspectives on treatment impact beyond clinician-reported and performance-based outcomes. Additionally, a safety analysis of several delandistrogene moxeparvovec clinical studies with up to 7.5 years of patient follow-up will be presented; pooled data will include treatment-related adverse events that most commonly occurred within the first 60 days post-infusion.
Sarepta will also present data from across its exon skipping franchise, including Phase 3 results from ESSENCE for golodirsen and casimersen. Also, a new real-world analysis that explores survival in patients treated with exon skipping medicines will be presented, as well as interim real-world findings from the Phase 4 EVOLVE study describing long-term safety and loss of ambulation as observed in clinical practice.
“At MDA we’re sharing data that reinforce dystrophin restoration as a foundational therapy and its ability to slow Duchenne disease progression over time,” said Louise Rodino-Klapac, Ph.D., president of research & development and technical operations, Sarepta. “We want to bring forward a data-driven view of treatment experience in clinical and real-world settings, including longer-term functional outcomes, pooled safety learnings, and caregiver-reporter perspectives that provide complementary insights into treatment effect in a subset of patients treated in EMBARK. Our goal is to ensure clinicians and families have the information they need to make treatment decisions with confidence.”
Sarepta Podium Presentation:
480LB: Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: EMBARK Functional Outcomes and Safety up to 3 Years Post-Infusion (late-breaker) | Poster: March 10 10:30 a.m. – 1:30 p.m. ET 4 – 4:30 p.m. ET 6 – 8 p.m. ET Oral: March 11 2:30 – 2:45 p.m. ET |
Sarepta Poster Presentations (*Denotes encore presentation) :
22 S: Efficacy and Safety of Golodirsen and Casimersen Compared with Placebo in Duchenne Muscular Dystrophy (ESSENCE): Phase 3 Topline Results | March 8 6 – 8 p.m. ET | |
25 S: 2025 Interim Analysis of EVOLVE: A Long-Term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice | March 8 6 – 8 p.m. ET | |
71 S: A Real-World Target Trial Emulation of Eteplirsen, Golodirsen, and Casimersen to Evaluate Survival Among Patients with Duchenne Muscular Dystrophy | March 8 6 – 8 p.m. ET | |
77 S: Caregiver Global Impressions of Delandistrogene Moxeparvovec in Patients with Duchenne Muscular Dystrophy: Findings from EMBARK 2-Year Follow-Up | March 8 6 – 8 p.m. ET | |
56 S: Model-Based Evaluation of Delandistrogene Moxeparvovec Adeno-Associated Virus Pharmacokinetics and Safety Implications* | March 8 6 – 8 p.m. ET | |
478LB: Pooled Safety Analysis from Phase 1 to Phase 3 Clinical Trials of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy (late-breaker) | March 10 10:30 – 1:30 p.m. ET 4 – 4:30 p.m. ET 6 – 8 p.m. ET | |
272 T: Quantitation of Dystrophin Expression in Patients with Duchenne Muscular Dystrophy by Western Blot Analysis Adjusted for Muscle Content | March 10 Poster Reception: 10:30 – 1:30 p.m. ET 4 – 4:30 p.m. ET 6 – 8 p.m. ET | |
319 T: Expression of SGCA and Safety Following Treatment with Patidistrogene Bexoparvovec in Patients with LGMD2D/R3: Results from a Phase 1b Study | March 10 Poster Reception: 10:30 – 1:30 p.m. ET 4 – 4:30 p.m. ET 6 – 8 p.m. ET |
The full MDA 2026 program is available here: https://www.mdaconference.org . Sarepta abstracts and presentations will be available on Sarepta.com in the Events & Presentations section following the MDA embargo.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn , X , Instagram and Facebook .
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com . We encourage investors and potential investors to consult our website regularly for important information about us.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements related to our research and development programs, clinical trials, technologies, scientific approaches, products and product candidates; and expected plans and milestones, including presenting certain data and findings at MDA.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; certain programs may never advance in the clinic or may be discontinued for a number of reasons, including regulators imposing a clinical hold and us suspending or terminating clinical research or trials; we may not be able to execute on our business plans, including meeting expected or planned regulatory milestones and timelines, clinical development plans, and bringing products to markets for various reasons including possible limitations of financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260226196021/en/
Investor Contacts:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Ryan Wong, 617-800-4112
rwong@sarepta.com
Tam Thornton, 617-803-3825
tthornton@sarepta.com
Media Contacts:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Kara Hoeger, 617-710-3898
khoeger@sarepta.com
FAQ**
How does Sarepta Therapeutics' focus on Duchenne muscular dystrophy compare to Agilent Technologies Inc. A's strategies in the biopharmaceutical sector?
2. What potential synergies could exist between the gene therapies developed by Sarepta Therapeutics and the technologies offered by Agilent Technologies Inc. A?
3. Considering Sarepta's upcoming presentations, how might the market react in comparison to recent performance by Agilent Technologies Inc. A?
4. How do the risk factors associated with Sarepta's product candidates parallel those faced by Agilent Technologies Inc. A in their R&D endeavors?
**MWN-AI FAQ is based on asking OpenAI questions about Agilent Technologies Inc. (NYSE: A).
NASDAQ: A
A Trading
-1.15% G/L:
$114.8825 Last:
1,021,829 Volume:
$113.93 Open:
